Initial ColoSTAT Assessment in UK opens new market access

• Successfully completed technology transfer of ColoSTAT to Southern Hub lab
• Supports pathway to international markets
• Next steps include analytical evaluation and clinical study

Rhythm Biosciences Ltd, an Australian company focused on predictive cancer diagnostics, announced that the Southern Hub Research Team at the Royal Surrey NHS Foundation Trust has successfully completed the technology transfer of ColoSTAT, its blood-based test for bowel cancer detection. This achievement marks the first phase of an independent evaluation, demonstrating that the assay can be operated by an external laboratory team. The next steps involve analytical evaluation and a clinical study, which, if successful, could provide independent clinical performance data for ColoSTAT in an NHS laboratory setting. This milestone positions Rhythm Biosciences to pursue laboratory partnerships in other key international markets.

The successful technology transfer positions Rhythm Biosciences to pursue laboratory partnerships in other international markets, subject to local regulatory approvals and commercial arrangements.